T he Convention on Biological Diversity (CBD) sets the policy framework for biodiversity conservation and sustainable use through the commitments of 195 countries and the European Union. The Strategic Plan for Biodiversity 2011-2020 included Aichi Biodiversity Target 12, which set the goal for 2020 of preventing the extinction of known threatened species and improving and sustaining their conservation status. Despite government commitments and successful efforts for certain species 1 , the overall extinction risk continues to increase, and widespread implementation shortfalls will prevent Target 12 from being met 2 . A new global framework with revised goals and targets is currently being negotiated, which places the stabilization and restoration of species' populations as an outcome goal for 2030, as a stepping stone towards the CBD's 2050 Vision 3,4 .

Biodiversity loss is a critical sustainability issue, and companies are beginning to seek ways to assess their biodiversity performance. Initiatives to date have developed biodiversity indicators for specific business contexts (e.g., spatial scales-from site, to product, to regional, or corporate scales); however, many are not widely translatable across different contexts making it challenging for businesses seeking indicators to manage their biodiversity performance. By synthesising the steps of common conservation and business decision-making systems, we propose a framework to support more comprehensive development of quantitative biodiversity indicators, for a range of business contexts. The framework integrates experience from existing tried-andtested conservation frameworks. We illustrate how our framework offers a pathway for businesses to assess their biodiversity performance and demonstrate responsible management by mitigating and reversing their biodiversity impacts and sustaining their dependencies, enabling them to demonstrate their contribution to emerging global biodiversity targets (e.g., Convention on Biological Diversity post-2020 targets).

Achieving a climate-resilient future requires rapid, sustained and far-reaching transformations in energy, land-use, infrastructure and industrial systems. Large-scale expansion of renewable energy can play a critical role in meeting the world’s growing energy demands and in the fight against climate change. However, even ‘clean’ energy sources can have significant unintended impacts on the environment. The guidelines aim to provide practical support for solar and wind energy developments by effectively managing risks and improving overall outcomes related to biodiversity and ecosystem services. They are industry-focused and can be applied across the whole project development life cycle, from early planning through to decommissioning and repowering, using the mitigation hierarchy as a clear framework for planning and implementation. The mitigation hierarchy is applied to direct, indirect and cumulative impacts.

The Brain is vulnerable to numerous insults that can act in the pre-, peri-, and post-natal period. There is growing evidence that demonstrate how oxidative stress (OS) could represent the final common pathway of all these insults. Fetuses and newborns are particularly vulnerable to OS due to their inability to active the antioxidant defenses. Specific molecules involved in OS could be measured in biologic fluids as early biomarkers of neonatal brain injury with an essential role in neuroprotection. Although S-100B seems to be the most studied biomarker, its use in clinical practice is limited by the complexity of brain damage etiopathogenesis and the time of blood sampling in relation to the brain injury. Reliable early specific serum markers are currently lacking in clinical practice. It is essential to determine if there are specific biomarkers that can help caregivers to monitor the progression of the disease in order to active an early neuroprotective strategy. We aimed to describe, in an educational review, the actual evidence on serum biomarkers for the early identification of newborns at a high risk of neurological diseases. To move the biomarkers from the bench to the bedside, the assays must be not only be of a high sensitivity but suitable for the very rapid processing and return of the results for the clinical practice to act on. For the best prognosis, more studies should focus on the association of these biomarkers to the type and severity of perinatal brain damage.